127 related articles for article (PubMed ID: 32893890)
1. Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations.
Zhai XY; Zhou Y; Dong L; Nie AQ; Zhi LJ; Jacqz-Aigrain E; Wang TY; Wang L; Zhao W
J Clin Pharm Ther; 2021 Feb; 46(1):74-77. PubMed ID: 32893890
[TBL] [Abstract][Full Text] [Related]
2. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
3. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.
Zhou Y; Wang L; Zhai XY; Wen L; Tang F; Yang F; Liu XT; Dong L; Zhi LJ; Shi HY; Hao GX; Zheng Y; Jacqz-Aigrain E; Wang TY; Zhao W
Br J Clin Pharmacol; 2020 Aug; 86(8):1519-1527. PubMed ID: 32077136
[TBL] [Abstract][Full Text] [Related]
4. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
Hale JP; Lilleyman JS
Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
[TBL] [Abstract][Full Text] [Related]
5. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
[TBL] [Abstract][Full Text] [Related]
6. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
[TBL] [Abstract][Full Text] [Related]
8. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
10. The Relationship of Genetics, Nursing Practice, and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology [Formula: see text].
Haylett WJ
J Pediatr Oncol Nurs; 2017; 34(5):342-346. PubMed ID: 28681659
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
13. [Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].
Dokmanović L; Janić D; Krstovski N; Zukić B; Tosić N; Pavlović S
Srp Arh Celok Lek; 2008; 136(11-12):609-16. PubMed ID: 19177822
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
15. Why more 6-mercaptopurine?
Kamen BA
Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746
[No Abstract] [Full Text] [Related]
16. [Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].
Hou YJ; Zhao L; Liu XX; Ma YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):622-6. PubMed ID: 27151041
[TBL] [Abstract][Full Text] [Related]
17. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
[TBL] [Abstract][Full Text] [Related]
20. Screening for mercaptopurine intolerance in ALL - target the genes or their product?
Barrett J
Br J Haematol; 2022 Oct; 199(2):173-174. PubMed ID: 36120820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
